Related references
Note: Only part of the references are listed.RETREG1/FAM134B mediated autophagosomal degradation of AMFR/GP78 and OPA1-a dual organellar turnover mechanism
Debdatto Mookherjee et al.
AUTOPHAGY (2021)
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 (2021)
The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
Ziyu Meng et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway
Yingnan Zhao et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
MIR210HG regulates glycolysis, cell proliferation, and metastasis of pancreatic cancer cells through miR-125b-5p/HK2/PKM2 axis
Tianzhu Yu et al.
RNA BIOLOGY (2021)
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
Yihai Liu et al.
JOURNAL OF INFLAMMATION RESEARCH (2021)
Hepatic PLIN5 signals via SIRT1 to promote autophagy and prevent inflammation during fasting[S]
Enxiang Zhang et al.
JOURNAL OF LIPID RESEARCH (2020)
The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice
Emily A. Day et al.
BIOCHEMICAL JOURNAL (2020)
Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
Arief Rahadian et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1
Qingling Jia et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2019)
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Patricia Marchio et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
Nannan Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2019)
NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
Daniela Stols-Goncalves et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2019)
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
Henith Raj et al.
WORLD JOURNAL OF DIABETES (2019)
Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
Kumiko Shiba et al.
SCIENTIFIC REPORTS (2018)
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Narjes Nasiri-Ansari et al.
CARDIOVASCULAR DIABETOLOGY (2018)
The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
Yusuke Nakatsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease
William Herrington et al.
CIRCULATION RESEARCH (2016)
Argininosuccinate synthetase regulates hepatic AMPK linking protein catabolism and ureagenesis to hepatic lipid metabolism
Anila K. Madiraju et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling
Hong Tang et al.
EBIOMEDICINE (2016)
Autophagy: a new target for nonalcoholic fatty liver disease therapy
Yuqing Mao et al.
HEPATIC MEDICINE-EVIDENCE AND RESEARCH (2016)
Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease
Simon Barquera et al.
ARCHIVES OF MEDICAL RESEARCH (2015)
Novel anti-inflammatory therapies for the treatment of atherosclerosis
Razi Khan et al.
ATHEROSCLEROSIS (2015)
Effect of High-Fat Diet on Hepatic Proteomics of Hamsters
Chen-Chung Liao et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2015)
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
Sanjay Kalra
DIABETES THERAPY (2014)
Regulation of lipid stores and metabolism by lipophagy
K. Liu et al.
CELL DEATH AND DIFFERENTIATION (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
Elizabeth M. Lamos et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
AMPK, insulin resistance, and the metabolic syndrome
Neil B. Ruderman et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
Melania Gaggini et al.
NUTRIENTS (2013)
Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance
Durba Pal et al.
NATURE MEDICINE (2012)
AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice
Yu Li et al.
CELL METABOLISM (2011)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2011)
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Joungmok Kim et al.
NATURE CELL BIOLOGY (2011)
Human Fatty Liver Disease: Old Questions and New Insights
Jonathan C. Cohen et al.
SCIENCE (2011)
JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease
Giovanni Tarantino et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Cardiovascular Risk Prediction Basic Concepts, Current Status, and Future Directions
Donald M. Lloyd-Jones
CIRCULATION (2010)
Nitric oxide - the endothelium-derived relaxing factor and its role in endothelial functions
Viktor Bauer et al.
GENERAL PHYSIOLOGY AND BIOPHYSICS (2010)
Apolipoprotein E knockout models
Genovefa Kolovou et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
DB Savage et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1)
J Haberle et al.
MOLECULAR GENETICS AND METABOLISM (2003)
Share Paper
